(NUVL) Nuvalent - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 7.987m USD | Total Return: 39.5% in 12m
Avg Turnover: 48.9M
Warnings
Interest Coverage Ratio -19.0 is critical
Altman Z'' -6.28 < 1.0 - financial distress zone
Choppy Below Avwap Earnings
Tailwinds
No distinct edge detected
Nuvalent, Inc. (NUVL) is a clinical-stage biopharmaceutical company focused on developing small-molecule kinase inhibitors for targeted cancer therapies. The firm specializes in creating brain-penetrant, selective inhibitors designed to overcome treatment resistance and central nervous system metastases in non-small cell lung cancer (NSCLC) and other solid tumors.
The company’s primary pipeline includes Zidesamtinib (NVL-520) for ROS1-positive cancers, Neladalkib (NVL-655) for ALK-positive cases, and NVL-330 for HER2-driven tumors. These assets are currently progressing through Phase 1 and Phase 2 clinical trials, targeting specific genetic mutations while attempting to minimize off-target toxicities common in traditional tyrosine kinase inhibitors.
The biotechnology sector often requires high research and development expenditure, as clinical-stage firms typically operate without product revenue until regulatory approval is secured. Nuvalent utilizes a structure-based drug design approach, which is a common business model for precision medicine companies seeking to improve the therapeutic window of existing drug classes.
Investors can evaluate the company’s clinical milestones and comparative pipeline positioning by exploring the data on ValueRay.
- Clinical data readouts from Zidesamtinib Phase 2 trials for ROS1-positive lung cancer
- FDA approval timelines and regulatory milestones for Neladalkib in ALK-positive NSCLC
- Penetration of brain-penetrant HER2 inhibitors into the competitive oncology treatment landscape
- R&D expenditure and cash burn rates impact long-term clinical development runway
- Strategic partnership success with Guardant Health for companion diagnostic development and commercialization
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.23 > 0.02 and ΔFCF/TA -5.07 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.23 > 3% & CFO -312.8m > Net Income -450.1m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 16.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (78.7m) vs 12m ago 9.86% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -19.03 > 6 (EBITDA TTM -24.6m / Interest Expense TTM 23.1m) |
| A: 0.92 (Total Current Assets 1.31b - Total Current Liabilities 81.1m) / Total Assets 1.33b |
| B: -0.81 (Retained Earnings -1.08b / Total Assets 1.33b) |
| C: -0.36 (EBIT TTM -438.9m / Avg Total Assets 1.22b) |
| D: -6.91 (Book Value of Equity -1.08b / Total Liabilities 156.8m) |
| Altman-Z'' = -6.28 = D |
As of May 24, 2026, the stock is trading at USD 101.24 with a total of 358,560 shares traded.
Over the past week, the price has changed by -0.18%,
over one month by -6.18%,
over three months by -0.85% and
over the past year by +39.45%.
Nuvalent has received a consensus analysts rating of 4.73. Therefore, it is recommended to buy NUVL.
- StrongBuy: 8
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 142.1 | 40.3% |
Revenue TTM = 0.0 USD
EBIT TTM = -438.9m USD
EBITDA TTM = -24.6m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 6.70b USD (7.99b + (null Debt) - CCE 1.29b)
Interest Coverage Ratio = -19.03 (Ebit TTM -438.9m / Interest Expense TTM 23.1m)
EV/FCF = -21.42x (Enterprise Value 6.70b / FCF TTM -312.8m)
FCF Yield = -4.67% (FCF TTM -312.8m / Enterprise Value 6.70b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 5.03 (Enterprise Value 6.70b / Total Assets 1.33b)
Interest Expense / Debt = unknown (Interest Expense 23.1m / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = -346.7m (EBIT -438.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 16.14 (Total Current Assets 1.31b / Total Current Liabilities 81.1m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA -24.6m)
Debt / FCF = unknown (Net Debt none / FCF TTM -312.8m)
Total Stockholder Equity = 1.05b (last 4 quarters mean from totalStockholderEquity)
RoA = -36.94% (Net Income -450.1m / Total Assets 1.33b)
RoE = -21.09% (Net Income TTM -450.1m / Total Stockholder Equity 2.13b)
RoCE = -35.11% (EBIT -438.9m / Capital Employed (Total Assets 1.33b - Current Liab 81.1m))
RoIC = -27.74% (negative operating profit) (NOPAT -346.7m / Invested Capital 1.25b)
WACC = 10.09% (E(7.99b)/V(7.99b) * Re(10.09%) + (debt-free company))
Discount Rate = 10.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 11.02%
[DCF] Fair Price = unknown (Cash Flow -312.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.43 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.38 | Chg30d=-0.31% | Revisions=+0% | Analysts=16
EPS next Quarter (2026-09-30): EPS=-1.40 | Chg30d=-0.53% | Revisions=+0% | Analysts=16
EPS current Year (2026-12-31): EPS=-5.45 | Chg30d=+0.85% | Revisions=+0% | GrowthEPS=+6.8% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.99 | Chg30d=+1.07% | Revisions=-18% | GrowthEPS=+26.8% | GrowthRev=+1333.5%
[Analyst] Revisions Ratio: -18%